3-chloro-N-(4-(pyridin-3-yloxy)pyridin-2-yl)benzamide | 1279460-32-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-chloro-N-(4-(pyridin-3-yloxy)pyridin-2-yl)benzamide
• 英文别名: 3-chloro-N-(4-pyridin-3-yloxypyridin-2-yl)benzamide
• CAS: 1279460-32-0
• 化学式: C₁₇H₁₂ClN₃O₂
• 分子量: 325.754
• InChiKey: DWDWCMMYVDXENC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-羟基吡啶 、 3-chloro-N-(4-chloropyridin-2-yl)benzamide 在 copper(l) iodide 、 N,N-二甲基甘氨酸盐酸盐 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以40%的产率得到3-chloro-N-(4-(pyridin-3-yloxy)pyridin-2-yl)benzamide
  参考文献：
  名称：

  [EN] SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME
  [FR] ANALOGUES D'HÉTÉROARYLAMINE CARBOXAMIDE SUBSTITUÉ UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR5, LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION

  摘要：

  本文揭示了代谢型谷氨酸受体亚型5（mGluR5）的负性别构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经病学和精神疾病的方法。本摘要旨在作为特定领域搜索的扫描工具，并不限制本发明的范围。

  公开号：

  WO2011035174A1

文献信息

• [EN] SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] ANALOGUES D'HÉTÉROARYLAMINE CARBOXAMIDE SUBSTITUÉ UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR5, LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：UNIV VANDERBILT

  公开号：WO2011035174A1

  公开（公告）日：2011-03-24

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention

  本文揭示了代谢型谷氨酸受体亚型5（mGluR5）的负性别构调节剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经病学和精神疾病的方法。本摘要旨在作为特定领域搜索的扫描工具，并不限制本发明的范围。
• SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME
  申请人：Conn P. Jeffrey

  公开号：US20110172247A1

  公开（公告）日：2011-07-14

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention

  本发明涉及负向变构谷氨酸受体亚型5（mGluR5）的负向变构调节剂；制备该化合物的合成方法；包含该化合物的药物组合物；以及使用该化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。该摘要旨在作为特定领域搜索的扫描工具，并不意味着对本发明的限制。
• Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
  申请人：Conn P. Jeffrey

  公开号：US08569308B2

  公开（公告）日：2013-10-29

  Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及一种代谢型谷氨酸受体亚型5（mGluR5）的负向变构调节剂；制备该化合物的合成方法；包含该化合物的制药组合物；以及使用该化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神障碍的方法。本摘要旨在作为特定领域搜索的扫描工具，并不意味着对本发明的限制。
• US8569308B2
  申请人：——

  公开号：US8569308B2

  公开（公告）日：2013-10-29
• Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety
  作者：Brittney S. Bates、Alice L. Rodriguez、Andrew S. Felts、Ryan D. Morrison、Daryl F. Venable、Anna L. Blobaum、Frank W. Byers、Kera P. Lawson、J. Scott Daniels、Colleen M. Niswender、Carrie K. Jones、P. Jeffrey Conn、Craig W. Lindsley、Kyle A. Emmitte

  DOI：10.1016/j.bmcl.2014.06.003

  日期：2014.8

  Development of SAR in an aryl ether series of mGlu(5) NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu(5) that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of V1J0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu(5) antagonists and other anxiolytics, produced dose proportional effects. (C) 2014 Elsevier Ltd. All rights reserved.